Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Geode Capital Management LLC grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 3.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,977,082 shares of the company’s stock after purchasing an additional 66,459 shares during the quarter. Geode Capital Management LLC owned about 2.32% of Syndax Pharmaceuticals worth $38,066,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Northwestern Mutual Wealth Management Co. purchased a new position in Syndax Pharmaceuticals during the 2nd quarter worth $27,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals in the third quarter worth about $30,000. nVerses Capital LLC purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter worth about $33,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals during the third quarter valued at about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares during the last quarter.

Analysts Set New Price Targets

Several research firms have weighed in on SNDX. UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price on the stock. Citigroup boosted their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. Stifel Nicolaus boosted their price target on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $36.90.

Syndax Pharmaceuticals Stock Down 1.8 %

Shares of SNDX opened at $13.07 on Wednesday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -3.60 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a 52 week low of $12.75 and a 52 week high of $25.34. The stock’s 50-day moving average price is $17.17 and its 200-day moving average price is $19.21.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the previous year, the firm posted ($0.73) earnings per share. As a group, equities analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).